PT  - JOURNAL ARTICLE
AU  - Pileri, S A
AU  - Ascani, S
AU  - Leoncini, L
AU  - Sabattini, E
AU  - Zinzani, P L
AU  - Piccaluga, P P
AU  - Pileri, A
AU  - Giunti, M
AU  - Falini, B
AU  - Bolis, G B
AU  - Stein, H
TI  - Hodgkin's lymphoma: the pathologist's viewpoint
DP  - 2002 Mar 01
TA  - Journal of Clinical Pathology
PG  - 162--176
VI  - 55
IP  - 3
4099  - http://jcp.bmj.com/content/55/3/162.short
4100  - http://jcp.bmj.com/content/55/3/162.full
SO  - J Clin Pathol2002 Mar 01; 55
AB  - Despite its well known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B cell derivation of the tumour in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognises a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (CHL), reflecting the differences in clinical presentation and behaviour, morphology, phenotype, and molecular features. CHL has been classified into four subtypes: lymphocyte rich, nodular sclerosing, with mixed cellularity, and lymphocyte depleted. The borders between CHL and anaplastic large cell lymphoma have become sharper, whereas those between LP-HL and T cell rich B cell lymphoma remain ill defined. Treatments adjusted to the pathobiological characteristics of the tumour in at risk patients have been proposed and are on the way to being applied.